Plk2 is epigenetically inactivated in malignant lymphomas (Smith et al. 2006), and silencing of Plk2 enhances tumor growth in non–small cell lung carcinoma, ovarian carcinoma, and gastric cancer (Coley et al. 2012; Matthew et al. 2007; Zhao et al. 2015). This evidence concerns the gene PLK2 and neoplasm.